Search Tag: ESC guidelines
2024 30 Aug
The 2024 ESC Guidelines on the management of chronic coronary syndromes (CCS) emphasise the importance of addressing both large and small blood vessels in the heart, introducing new models to estimate the likelihood of obstructive coronary artery disease, optimising the selection and sequencing of diagnostic tests, and recommending drugs and interventions...Read more
2022 15 Feb
The new ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure outline ten key messages: The guidelines recommend an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a sodium-glucose co-transporter 2 inhibitor to reduce...Read more
2021 30 Sep
In 2020, the ultra-short acting beta-blocker landiolol was first included in the ESC guidelines with a class I recommendation. The recommendations were based on study results demonstrating the rapid response, efficacy, and safety of this drug. At a recent symposium, during 2021 Heart Failure World Congress, cardiologists were invited to present...Read more
2019 02 Oct
Summary: A presentation of a case study in light of the updated ESC guidelines on lipid control and new guidelines on diabetes and cardiovascular disease. Several new guidelines were released at the European Society of Cardiology (ESC) Congress in Paris, France. These included updated guidelines on lipid control and new guidelines...Read more
2019 03 Sep
At the ESC Congress this year, several new guidelines have been released including updated guidelines on lipid control and new guidelines on diabetes and cardiovascular disease. As per the updated guidelines on lipid control , the following are some key recommendations: Low-density lipoprotein (LDL) cholesterol levels should be lowered...Read more
2019 24 Jan
There is significant clinical evidence that suggests a strong association between low-density lipoprotein (LDL)-cholesterol with risk of coronary artery disease (CAD) events and the reduction of cardiovascular events in secondary prevention. Based on this evidence, the European Society of Cardiology incorporated low-density lipoprotein targets...Read more
2015 17 Feb
Coronary patients in Europe are not meeting lifestyle, therapeutic and risk factor targets after hospitalisation A new approach to the secondary prevention of coronary disease is called for The large majority of coronary patients in Europe are failing to achieve their lifestyle, risk factor and therapeutic targets as set out in the latest prevention...Read more
2014 02 Sep
One of the most important treatment principles in cardiology includes myocardial revascularisation by percutaneous coronary intervention (PCI) or surgical placement of coronary artery bypass grafts (CABG). However, in order to use these principles effectively, it is important to identify patients who require revascularisation as well as accurately...Read more
2014 01 Sep
This year's ESC Congress will see the launch of five new ESC Guidelines: Non-Cardiac Surgery, Acute Pulmonary Embolism, Hypertrophic Cardiomyopathy, Aortic Diseases and Myocardial Revascularization. The first was developed jointly with the European Society of Anesthesiology and the last with the European Society of Thoracic Surgery. The guidelines...Read more